DE60136826D1 - Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs - Google Patents

Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs

Info

Publication number
DE60136826D1
DE60136826D1 DE60136826T DE60136826T DE60136826D1 DE 60136826 D1 DE60136826 D1 DE 60136826D1 DE 60136826 T DE60136826 T DE 60136826T DE 60136826 T DE60136826 T DE 60136826T DE 60136826 D1 DE60136826 D1 DE 60136826D1
Authority
DE
Germany
Prior art keywords
cancer
treatment
acid
asicic
asicaticoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136826T
Other languages
German (de)
English (en)
Inventor
Se-Kyung Oh
Chokyun Rha
Kadir Azizol Abdul
Lean Teik Ng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of Malaysia
Massachusetts Institute of Technology
Original Assignee
Government of Malaysia
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of Malaysia, Massachusetts Institute of Technology filed Critical Government of Malaysia
Application granted granted Critical
Publication of DE60136826D1 publication Critical patent/DE60136826D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60136826T 2000-08-29 2001-02-14 Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs Expired - Lifetime DE60136826D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI20003987A MY138883A (en) 2000-08-29 2000-08-29 Use of asiatic acid for treatment of cencer
PCT/US2001/040103 WO2002017904A1 (en) 2000-08-29 2001-02-14 Use of asiatic acid or asiaticoside for treatment of cancer

Publications (1)

Publication Number Publication Date
DE60136826D1 true DE60136826D1 (de) 2009-01-15

Family

ID=19749475

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136826T Expired - Lifetime DE60136826D1 (de) 2000-08-29 2001-02-14 Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs

Country Status (9)

Country Link
US (1) US20040097463A1 (enExample)
EP (1) EP1313462B1 (enExample)
JP (2) JP2004507496A (enExample)
AT (1) ATE415962T1 (enExample)
AU (1) AU2001247968A1 (enExample)
DE (1) DE60136826D1 (enExample)
DK (1) DK1313462T3 (enExample)
MY (1) MY138883A (enExample)
WO (1) WO2002017904A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
KR100571886B1 (ko) 2004-02-23 2006-04-17 학교법인 영남학원 아시아틱산을 포함하는 피부암 예방 또는 치료용 조성물
ATE514434T1 (de) 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
WO2006012015A2 (en) * 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
US20070010459A1 (en) * 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
CA2595749A1 (en) * 2005-01-27 2006-08-03 Research Development Foundation Combination therapy with triterpenoid compounds and proteasome inhibitors
JP5539224B2 (ja) * 2008-01-11 2014-07-02 シャンハイ・インスティチュート・オブ・ファーマシューティカル・インダストリー（エスアイピーアイ） アジアティック酸（ａｓｉａｔｉｃａｃｉｄ）及びその選択される塩に基づく治療用製剤
WO2009128936A2 (en) 2008-04-16 2009-10-22 The Johns Hopkins University Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
CN102725133B (zh) 2009-12-21 2016-03-23 倍耐力轮胎股份公司 控制制备轮胎设备生产周期的方法、构造轮胎的工艺及设备
JP5913297B2 (ja) 2010-06-10 2016-04-27 インダス バイオテック プライベート リミティド センテラ・アジアティカからの高純度アジアチコサイドの製造法及びその使用法
EP2648721B1 (de) * 2011-01-31 2018-09-19 LUCOLAS-M.D. Ltd. Kombinationen von aromatase inhibitoren und antioxidanzien
US20140194368A1 (en) * 2013-01-04 2014-07-10 Beech Tree Labs, Inc. Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70)
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
CA2910584A1 (en) * 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10774387B2 (en) 2014-05-19 2020-09-15 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
CA2959336A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
EP3124047A1 (en) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Pentacyclic triterpenoids for injection lipolysis
CN108057034A (zh) * 2016-11-09 2018-05-22 香港中文大学 柚皮素和积雪草酸组合治疗癌症
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2019200585A1 (en) * 2018-04-19 2019-10-24 The Chinese University Of Hong Kong Naringenin and asiatic acid combination treatment of cancers
US12173065B2 (en) * 2018-10-18 2024-12-24 Sinomab Bioscience Limited Fusion proteins comprising extracellular domain of human CD22
CN109528735B (zh) * 2019-01-30 2021-03-12 中国药科大学 积雪草苷在制备治疗皮肤癌药物中的新用途
CN110200981A (zh) * 2019-06-06 2019-09-06 中国药科大学 五环三萜皂苷的医药用途及其药物组合物
US20240034788A1 (en) * 2020-08-20 2024-02-01 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
WO2025188669A1 (en) * 2024-03-04 2025-09-12 Cardiff Oncology, Inc. Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB923414A (en) * 1960-04-13 1963-04-10 Laroche Navarron Lab Therapeutic compositions comprising asiatic and arjunolic acids
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
EP0383171A3 (en) * 1989-02-11 1991-07-24 Hoechst Aktiengesellschaft 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders
FR2714598B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition amincissante à deux types de liposomes pour traitement topique, son utilisation.
JPH08133952A (ja) * 1994-11-07 1996-05-28 Shiseido Co Ltd 皮膚外用剤
WO1998023575A1 (en) * 1996-11-27 1998-06-04 Dong Kook Pharmaceutical Co., Ltd. Asiatic acid derivatives having modified a-ring
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
FR2763336B1 (fr) * 1997-05-14 1999-08-06 Lvmh Rech Esters de tocopherol et leurs utilisations en cosmetique et pharmacie
WO2005120495A1 (en) * 2004-06-14 2005-12-22 Salama Zoser B Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody

Also Published As

Publication number Publication date
JP2012092110A (ja) 2012-05-17
EP1313462A1 (en) 2003-05-28
MY138883A (en) 2009-08-28
WO2002017904A1 (en) 2002-03-07
US20040097463A1 (en) 2004-05-20
ATE415962T1 (de) 2008-12-15
JP2004507496A (ja) 2004-03-11
EP1313462B1 (en) 2008-12-03
DK1313462T3 (da) 2009-03-30
AU2001247968A1 (en) 2002-03-13
JP5421340B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
PT1153024E (pt) 2-amino-6-anilino-purinas e sua utilizacao como medicamentos
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69508192D1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
EP1484366A4 (en) TREATED PIGMENT, USE THEREOF AND COMPOUND FOR TREATING PIGMENTS
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE60030554T8 (de) Verwendungen von et743 zur behandlung von krebs
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
DE602004016950D1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens
ATE406868T1 (de) Verwendung einer zusammensetzung mit vitamin k1- oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition